ReviewInternational journal of clinical oncology2025
Multidisciplinary treatment for advanced gastric cancer.
Review in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A prognostic senescence-related long non-coding RNA signature identifies cold and hot tumors of stomach adenocarcinoma.Oncology letters · 2026Article
- Dihydrocapsaicin suppresses the migration and invasion of gastric cancer cells by upregulating TRPV1 expression.In vitro cellular & developmental biology. Animal · 2026Article
- Hypericin-loaded small extracellular vesicles increase photodynamic therapy and remodel miRNA-mRNA axes in AGS gastric cancer cells.Scientific reports · 2026Article
- Sintilimab Plus Nanoparticle Polymeric Micellar Paclitaxel and S-1 as First-Line Treatment in HER2-Negative Advanced Gastric Cancer: A Real-World Study.Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outcomes for advanced gastric cancer are improving with multidisciplinary treatment combining surgical resection and perioperative chemotherapy. In Asia, the standard of care for pathological Stage (pStage) II gastric cancer involves tegafur-gimeracil-oteracil potassium for 1 year postoperatively after gastrectomy with D2 lymph node dissection or capecitabine plus oxaliplatin for 6 months postoperatively. For pStage III gastric cancer, a combination of tegafur, gimeracil, and oteracil potassium combined with docetaxel remains the standard postoperative treatment. However, perioperative chemotherapy combined with surgery is being developed to further improve outcomes, similar to approaches in Europe. In addition, the perioperative use of molecularly targeted agents, such as trastuzumab, and immune checkpoint inhibitors, such as pembrolizumab, is expected to improve outcomes. Furthermore, improved chemotherapy outcomes have increased opportunities for surgical intervention in Stage IV gastric cancer, which was previously not indicated for surgery. In this article, we reviewed multidisciplinary treatments for Stage II-IV gastric cancer, combining surgery and chemotherapy.
Indexed as
Identifiers
40439973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.